Azitra, Inc. (AZTR)

USD 0.38

(-9.91%)

Gross Profit Summary of Azitra, Inc.

  • Azitra, Inc.'s latest annual gross profit in 2023 was 260.45 Thousand USD , up 313.52% from previous year.
  • Azitra, Inc.'s latest quarterly gross profit in 2024 Q2 was -106.44 Thousand USD , up 7.37% from previous quarter.
  • Azitra, Inc. reported a annual gross profit of -121.97 Thousand USD in annual gross profit 2022, down -583.5% from previous year.
  • Azitra, Inc. reported a annual gross profit of 25.22 Thousand USD in annual gross profit 2021, down 0.0% from previous year.
  • Azitra, Inc. reported a quarterly gross profit of -114.91 Thousand USD for 2024 Q1, down -521.12% from previous quarter.
  • Azitra, Inc. reported a quarterly gross profit of 198.19 Thousand USD for 2023 Q3, up 179.75% from previous quarter.

Annual Gross Profit Chart of Azitra, Inc. (2023 - 2021)

Historical Annual Gross Profit of Azitra, Inc. (2023 - 2021)

Year Gross Profit Gross Profit Growth
2023 260.45 Thousand USD 313.52%
2022 -121.97 Thousand USD -583.5%
2021 25.22 Thousand USD 0.0%

Peer Gross Profit Comparison of Azitra, Inc.

Name Gross Profit Gross Profit Difference
AIM ImmunoTech Inc. 160 Thousand USD -62.782%
Ampio Pharmaceuticals, Inc. -250 Thousand USD 204.18%
Armata Pharmaceuticals, Inc. -29.24 Million USD 100.891%
Actinium Pharmaceuticals, Inc. -709 Thousand USD 136.735%
Can-Fite BioPharma Ltd. 743 Thousand USD 64.946%
Chromocell Therapeutics Corporation -2.57 Million USD 110.097%
Calidi Biotherapeutics, Inc. -1.25 Million USD 120.737%
CEL-SCI Corporation -3.95 Million USD 106.58%
iBio, Inc. -1.02 Million USD 125.41%
Lineage Cell Therapeutics, Inc. 8.27 Million USD 96.852%
MAIA Biotechnology, Inc. - USD -Infinity%
Matinas BioPharma Holdings, Inc. -13.39 Million USD 101.945%
Navidea Biopharmaceuticals, Inc. -119.29 Thousand USD 318.325%
NovaBay Pharmaceuticals, Inc. 7.89 Million USD 96.701%
NanoViricides, Inc. -759.01 Thousand USD 134.314%
Oragenics, Inc. -15.45 Million USD 101.685%
BiomX Inc. -1.22 Million USD 121.209%
BiomX Inc. -1.22 Million USD 121.209%
Protalix BioTherapeutics, Inc. 42.51 Million USD 99.387%
Palatin Technologies, Inc. 4.39 Million USD 94.07%
Scorpius Holdings, Inc. -2.21 Million USD 111.751%